Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing, China.
Department of Pathology, Peking Union Medical College Hospital, Beijing, China.
Thorac Cancer. 2020 Jul;11(7):2014-2017. doi: 10.1111/1759-7714.13427. Epub 2020 May 11.
The main recurrence pattern for lung cancer patients after radical surgery is distant metastasis. The probability of pancreatic metastasis in patients diagnosed with lung squamous cell carcinoma is 0.02%, with a poor prognosis. Chemotherapy is the preferred treatment for recurrence. Single lesions or oligometastasis can be surgically resected, and local lesions with compression symptoms can be treated with radiotherapy. The FDA and NMPA have approved first-line indications for immunotherapy for lung squamous cell carcinoma. Here, we report the case of a 57-year-old male patient with lung squamous cell carcinoma who developed pancreatic metastasis after radical resection. The disease progressed after first-line chemotherapy, and the patient was treated with immunotherapy combined with radiotherapy. We subsequently observed the abscopal effect of intensity modulated radiation therapy (IMRT) and pembrolizumab with disappearance of lung metastasis after radiotherapy for pancreatic metastasis. The patient's tumor symptoms were relieved with prolonged survival.
肺癌患者根治术后的主要复发模式是远处转移。诊断为肺鳞癌的患者发生胰腺转移的概率为 0.02%,预后较差。化疗是复发后的首选治疗方法。单发或寡转移病灶可手术切除,局部有压迫症状的病灶可采用放疗。FDA 和 NMPA 已批准免疫疗法用于肺鳞癌的一线治疗。本文报道了 1 例 57 岁男性肺鳞癌患者根治术后发生胰腺转移,一线化疗后疾病进展,给予免疫联合放疗治疗。我们随后观察到调强放疗(IMRT)和帕博利珠单抗的远隔效应,胰腺转移放疗后肺转移消失。患者的肿瘤症状缓解,生存期延长。